ArticleScientific reports2016
Iron(II) supramolecular helicates interfere with the HIV-1 Tat-TAR RNA interaction critical for viral replication.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Screening of metallohelices for enantioselective targeting SARS-CoV-2 RNA G-quadruplex.Nucleic acids research · 2025Article
- Structural and computational studies of HIV-1 RNA.RNA biology · 2024Review
- HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response.Expert review of hematology · 2022Article
- Supramolecular Cylinders Target Bulge Structures in the 5' UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication*.Angewandte Chemie (International ed. in English) · 2021Article
- Supramolecular Cylinders Target Bulge Structures in the 5' UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2021Article
- Metal-Coordinated Supramolecular Self-Assemblies for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Targeting structural features of viral genomes with a nano-sized supramolecular drug.Chemical science · 2021Article
- Metallohelices emulate the properties of short cationic α-helical peptides.Chemical science · 2021Review
- Cavity-Containing [FeFrontiers in chemistry · 2021Article
- Review
- Induction of a Four-Way Junction Structure in the DNA Palindromic Hexanucleotide 5'-d(CGTACG)-3' by a Mononuclear Platinum Complex.Angewandte Chemie (International ed. in English) · 2019Article
- Recent Developments of Supramolecular Metal-based Structures for Applications in Cancer Therapy and Imaging.Theranostics · 2019Review
- Metallo supramolecular cylinders inhibit HIV-1 TAR-TAT complex formation and viral replication in cellulo.Scientific reports · 2018Article
- Biomedical Applications of Metallosupramolecular Assemblies-Structural Aspects of the Anticancer Activity.Frontiers in chemistry · 2018Review
- Antimicrobial Activity and Cytotoxicity of Ag(I) and Au(I) Pillarplexes.Frontiers in chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction between the HIV-1 transactivator protein Tat and TAR (transactivation responsive region) RNA, plays a critical role in HIV-1 transcription. Iron(II) supramolecular helicates were evaluated for their in vitro activity to inhibit Tat-TAR RNA interaction using UV melting studies, electrophoretic mobility shift assay, and RNase A footprinting. The results demonstrate that iron(II) supramolecular helicates inhibit Tat-TAR interaction at nanomolar concentrations by binding to TAR RNA. These studies provide a new insight into the biological potential of metallosupramolecular helicates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.